Skip to main content

Table 4 Clinical, microbiological, and global response rates at various pre-defined efficacy timepoints throughout the study in the MITT population

From: Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial

  MITT population
Timepoint Clinical response, % [n /N] (95% CI) Microbiological response, % [n /N] (95% CI) Global response, % [n /N] (95% CI)
End of intravenous treatment 81.0 [34/42] 85.7 [36/42] 78.6 [33/42]
(65.9–91.4) (71.5–94.6) (63.2–89.7)
2 weeks after EOT 83.9 [26/31] 80.6 [25/31] 75.0 [24/32]
(66.3–94.5) (62.5–92.5) (56.6–88.5)
6 weeks after EOT 56.7 [17/30] 56.7 [17/30] 54.8 [17/31]
(37.4–74.5) (37.4–74.5) (36.0–72.7)
12 weeks after baseline 54.8 [17/31] 51.6 [16/31] 50.0 [16/32]
(36.0–72.7) (33.1–69.8) (31.9–68.1)
  1. Abbreviations used: CI, confidence interval; EOT, end of all treatment; MITT, modified intent-to-treat.